Amberfarma - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 194,129 | 234,039 | 292,724 | 297,464 | 295,120 | 299,593 | 350,201 | 403,716 |
| Profit before tax | 35,367 | 51,830 | 80,453 | 85,218 | 65,420 | 42,417 | 82,166 | -236,766 |
| Net profit | 33,504 | 49,135 | 76,316 | 80,880 | 62,079 | 40,192 | 69,309 | -236,766 |
| Equity | 94,478 | 111,613 | 128,929 | 139,809 | 166,888 | 147,080 | 532,481 | 122,715 |
| Liabilities | 47,952 | 49,187 | 97,648 | 69,497 | 89,711 | 27,556 | 67,725 | 42,209 |
| Non-current assets | 17,647 | 13,517 | 8,757 | 6,070 | 25,751 | 21,398 | 426,538 | 18,924 |
| Current assets | 124,231 | 146,823 | 217,355 | 202,805 | 230,014 | 152,351 | 172,694 | 144,978 |
| Total assets | 141,878 | 160,340 | 226,112 | 208,875 | 255,765 | 173,749 | 599,232 | 163,902 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 66,071 | 73,360 | 138,937 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -7.3% | +20.6% | +25.1% | +1.6% | -0.8% | +1.5% | +16.9% | +15.3% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 23.6% | 30.6% | 33.8% | 38.7% | 24.3% | 23.1% | 11.6% | -144.5% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 35.5% | 44.0% | 59.2% | 57.9% | 37.2% | 27.3% | 13.0% | -192.9% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 17.3% | 21.0% | 26.1% | 27.2% | 21.0% | 13.4% | 19.8% | -58.6% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 18.2% | 22.1% | 27.5% | 28.6% | 22.2% | 14.2% | 23.5% | -58.6% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.5 | 0.4 | 0.8 | 0.5 | 0.5 | 0.2 | 0.1 | 0.3 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 194,129 | 234,039 | 292,724 | 274,591 | 141,660 | 99,864 | 116,734 | 124,220 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Amberfarma - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2023-11-16 | 2023-11-20 | 0.17 |
| 2023-10-25 | 2023-11-05 | 0.17 |
| 2023-07-18 | 2023-07-23 | 100.00 |
Amberfarma - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Amberfarma, UAB (code 302578874) is a Private Limited Liability Company operating in wholesale of other food. In 2025, the latest financial year, revenue increased to €403.7K, up 15.3% year on year and 34.8% over two years. However, profitability weakened sharply: net profit fell to a loss of €236.8K, compared with profit of €69.3K in 2024 and €40.2K in 2023. The 2025 profit margin was -58.6%, indicating a significant reversal from the 19.8% margin recorded in 2024. The balance sheet also contracted, with total assets declining to €163.9K from €599.2K a year earlier, while equity fell to €122.7K and liabilities stood at €42.2K. The equity ratio was 74.9% and debt-to-equity 0.34, suggesting moderate leverage despite the weaker results. Asset turnover was 2.46x, and revenue per employee was €134.6K. Overall, 2025 shows a business with growing sales but a substantial deterioration in profitability and a smaller asset base.